[Bispecific antibodies targeting CD3 in oncology and hematology].
Anticorps bispécifiques ciblant CD3 en oncologie solide et onco-hématologie.
Antibodies, Bispecific
/ immunology
Antigens, CD19
/ immunology
Antigens, CD20
/ immunology
Antigens, Neoplasm
/ immunology
Breast Neoplasms
/ immunology
CD3 Complex
/ immunology
Digestive System Neoplasms
/ immunology
Female
Humans
Immune Tolerance
Immunotherapy, Adoptive
/ methods
Leukemia
/ immunology
Lung Neoplasms
/ immunology
Lymphoma
/ immunology
Male
Multiple Myeloma
/ immunology
Neoplasms
/ immunology
Prostatic Neoplasms
/ immunology
Small Cell Lung Carcinoma
/ immunology
T-Lymphocytes
/ immunology
Anticorps bispécifiques
BiTEs
Bispecifi-antibodies
Immunotherapy
Immunothérapie
T-cell engagers
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
04
03
2021
revised:
11
06
2021
accepted:
11
06
2021
entrez:
18
12
2021
pubmed:
19
12
2021
medline:
30
12
2021
Statut:
ppublish
Résumé
Bispecific therapies targeting CD3, so-called T-cell engagers (TCE), belong to the new spectrum of anti-tumor immunotherapies stimulating T-lymphocytes. TCE are unique constructs targeting the MHC-independent CD3 epsilon subunit (CD3e) and a tumor antigen. To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19. Other TCE are in advances development, with promising results targeting CD20 and BSMA in lymphoma and myeloma. These successes have relaunched the development of TCE in solid tumors, bringing mixed results so far (notably in terms of tolerance). Still, TCE pave the way to new immunotherapy in tumors considered to be refractory to inhibitors of immune checkpoints such as prostate cancer or colorectal cancer.
Identifiants
pubmed: 34920802
pii: S0007-4551(21)00257-5
doi: 10.1016/j.bulcan.2021.06.003
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Antigens, CD19
0
Antigens, CD20
0
Antigens, Neoplasm
0
CD19 molecule, human
0
CD3 Complex
0
CD3E protein, human
0
blinatumomab
4FR53SIF3A
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
S181-S194Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.